2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder J, Galsky M, Marron T, Smith C, LoRusso P, Hofstatter E, Doroshow D. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice 2024, op2400293. PMID: 39661920, DOI: 10.1200/op.24.00293.Peer-Reviewed Original ResearchEarly-phase clinical trialsSolid tumorsClinical trialsAssociated with higher FTFinancial toxicityBarriers to clinical trial enrollmentAdvanced solid malignanciesAdvanced solid tumorsInverse association with ageBaseline to 2 monthsYale Cancer CenterCOST scoreClinical trial enrollmentProspective survey studySolid malignanciesNo significant differenceBaseline FTTime of consentNovel therapiesPrimary outcomeCancer CenterSurvey 1Trial enrollmentPatientsEarly-phase
2017
Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancer